Indivior Share Price
48.86p
2.0 4.3%
market vs.
industry Growth & Value
| 12m Forecast Rolling | ||||
| PE Ratio (f) | n/a |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 3.27 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry Quality
| Year End 31st Dec | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | TTM | 2019E | 2020E | CAGR / Avg | |
| Revenue | $m | ||||||||||
| Operating Profit | $m | ||||||||||
| Net Profit | $m | ||||||||||
| EPS Reported | $ | ||||||||||
| EPS Normalised | $ | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | $ | ||||||||||
| Capex ps | $ | ||||||||||
| Free Cashflow ps | $ | ||||||||||
| Last ex-div: 16th Jun, paid: 29th Jul more... Dividends | |||||||||||
| Dividend ps | $ | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | $m | ||||||||||
| Working Capital | $m | ||||||||||
| Net Fixed Assets | $m | ||||||||||
| Net Debt | $m | ||||||||||
| Book Value | $m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | $ | ||||||||||
| Leverage (ttm) | Total | -Intang | +Pension | ||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % |
| Liquidity (ttm) | ||
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | |
| Asset Turnover | |
| Rec's Turnover | |
| Stock Turnover | |
market vs.
industry Recent History
| Latest interim period (ended 31st Mar '19) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Compound Annual Growth Rate | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
Broker Consensus Trend
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 5 | 0 | 1 |
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia. Its products are Suboxone Film (buprenorphine and naloxone), Suboxone Tablet (buprenorphine and naloxone), and Subutex Tablet (buprenorphine). Its other products include RBP-6000 in ATRIGEL, RBP-7000 risperidone monthly depot, Arbaclofen placarbil for alcohol use disorder (AUD), Intranasal naloxone for treatment of opioid overdose and RBP-8000 cocaine esterase for cocaine intoxication. Its RBP-6000 buprenorphine monthly depot is developed for the treatment of opioid use disorder. Its RBP-7000 risperidone monthly depot is developed for treatment of schizophrenia.
Directors: Howard Pien (CHM) , Shaun Thaxter (CEO) , Mark Crossley (CFO) , Jon Fogle (CHO) , Ingo Elfering (CIO) , Christian Heidbreder (CSO) , Debby Betz (OTH) , Javier Rodriguez (OTH) , Richard Simkin (OTH) , Frank Stier (OTH) , Tatjana May (NED) 50, A. Thomas McLellan (NED) , Daniel Tasse (IND) 58, Lorna Parker (NID) , Daniel Phelan (NID) 69,
No. of Employees: 1,024 No. of Shareholders: n/a
| Last Annual | December 31st, 2018 |
| Last Interim | March 31st, 2019 |
| Incorporated | September 26, 2014 |
| Public Since | December 23, 2014 |
| Shares in Issue | 730,030,588 |
| Free Float | 726.4m (99.5%) |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE All Share , FTSE All Share Health Care , FTSE All Share Pharmaceuticals & Biotechnology , FTSEurofirst 300 Ex Eurozone, FTSE 350 , FTSE 350 Lower Yield , FTSE 250 , FTSE 350 Pharmaceuticals & Biotechnology , , |
| Exchange |
London Stock Exchange (Full)
|
| Eligible for | an ISA? a SIPP? |
| Address | 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom |
| Web | http://indivior.com/ |
| Phone | +44 1753 217800 |
| Contact | () |
| Auditors | PricewaterhouseCoopers LLP |
Recent ↓
Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.
